Mainstream

AstraZeneca beats Q4 top-line and bottom-line estimates; initiates FY25 outlook

AstraZeneca beats Q4 top-line and bottom-line estimates; initiates FY25 outlook

Post Contentazn, azncfRead More

You might also be interested in reading Andreessen Horowitz leads $25m round for Optimism’s L2 scaling solution.

February 6, 2025
In Mainstream